Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization


Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based

Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today reported

Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021


Regulatory News:



NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand

Transgene Announces Upcoming Investor Meetings: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Upcoming Investor Meetings


Regulatory News:



Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021


Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields : https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields


Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR)

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results

Community Healthcare System Partners with Premier, Inc. to Drive Operational Innovation and High-Quality Patient Care: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Community Healthcare System Partners with Premier, Inc. to Drive Operational Innovation and High-Quality Patient Care


Community Healthcare System, recognized for high-quality care across Northwest Indiana, has partnered with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company. Through this new

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in

NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research (AACR) Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Highlights Spatial Biology Research from the 2021 American Association of Cancer Research (AACR) Conference


NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of spatial biology abstracts that

NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F


Regulatory News:



NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities

Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021


Regulatory News:



Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary

Lantheus Expands R&D Leadership Team with Key New Hires
Lantheus Expands R&D Leadership Team with Key New Hires


Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions

Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received initial

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment

Dexcom Starts Direct Distribution in the Netherlands: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Starts Direct Distribution in the Netherlands


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope

Dexcom Starts Direct Distribution in the Netherlands: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Starts Direct Distribution in the Netherlands


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distribution collaboration with Zkope

Premier, Inc. to Report Fiscal 2021 Third-Quarter Results and Host Conference Call on May 4, 2021: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2021 Third-Quarter Results and Host Conference Call on May 4, 2021


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 third quarter on Tuesday, May 4, 2021, at approximately 6:30 a.m. ET. The company will also

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021


Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021


Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021


Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021 http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021


Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of a presentation and conference call with investment analysts at 10 a.m. EDT on Friday, April 9

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021 http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021


Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of a presentation and conference call with investment analysts at 10 a.m. EDT on Friday, April 9